» Articles » PMID: 24355634

Pulmonary Hypertension Due to Left Heart Diseases

Abstract

Pulmonary hypertension (PH), a common complication of left heart diseases (LHD), negatively impacts symptoms, exercise capacity, and outcome. Although the true prevalence of PH-LHD is unknown, a subset of patients might present significant PH that cannot be explained by a passive increase in left-sided filling pressures. The term "out-of-proportion" PH has been used to identify that population without a clear definition, which has been found less than ideal and created confusion. We propose a change in terminology and a new definition of PH due to LHD. We suggest to abandon "out-of-proportion" PH and to distinguish "isolated post-capillary PH" from "post-capillary PH with a pre-capillary component" on the basis of the pressure difference between diastolic pulmonary artery pressure and pulmonary artery wedge pressure. Although there is no validated treatment for PH-LHD, we provide insights into management and discuss completed and randomized trials in this condition. Finally, we provide recommendations for future clinical trials to establish safety and efficacy of novel compounds to target this area of unmet medical need.

Citing Articles

Mechanisms of exercise intolerance in hear-t failure with preserved ejection fraction (HFpEF).

Pecchia B, Samuel R, Shah V, Newman E, Gibson G Heart Fail Rev. 2025; .

PMID: 40080287 DOI: 10.1007/s10741-025-10504-3.


Sarcoidosis-Associated Pulmonary Hypertension.

Morimatsu Y, Tahara N, Okamoto M, Bekki M, Tahara A, Eto Y Medicina (Kaunas). 2025; 61(2).

PMID: 40005458 PMC: 11857724. DOI: 10.3390/medicina61020342.


Tricuspid annular plane systolic excursion/pulmonary arterial systolic pressure ratio as a predictor of outcome in acute heart failure.

Antit S, Mrabet A, Fathi M, Fekih R, Boussabeh E, Zakhama L Tunis Med. 2025; 103(1):104-111.

PMID: 39812202 PMC: 11906249. DOI: 10.62438/tunismed.v103i1.5365.


Association of daily physical activity with pulmonary artery pressure in HFpEF and HFmrEF NYHA class III patients: a pilot trial-feasibility and first results.

Herrmann E, Lange D, Hannig J, Zimmer G, Gruen D, Keller T Clin Res Cardiol. 2024; .

PMID: 39508889 DOI: 10.1007/s00392-024-02564-6.


CD8 T cells promote heart failure progression in mice with preexisting left ventricular dysfunction.

Wang D, Weng X, Yue W, Shang L, Wei Y, Clemmer J Front Immunol. 2024; 15:1472133.

PMID: 39324134 PMC: 11422781. DOI: 10.3389/fimmu.2024.1472133.